Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

16260 Ventura Blvd., Suite 140
Encino, CA 91436
Phone: 818-528-7776

December 5, 2021 by Alan Khadavi

Gefapixant for Chronic Cough by Merck

Gefapixant is a selective P2X3 receptor antagonist being currently developed by Merck for chronic unexplained cough. Chronic cough is a significant issue for many patients. It is estimated that between 5-10% of the population has it at one time. Many patients with chronic cough have underlying allergies that cause post nasal drip, asthma or acid reflux disease. But some patients have no explanation for their coughs after extensive testing. The coughs can be triggered by “talking, laughing, a change in air temperature or exposure to aerosols or food odors, and to date treatment options are extremely limited for these patients,” said Dr. Lorcan McGarvey, Clinical Professor, Wellcome-Wolfson Institute of Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast.

We discussed cough in several blog posts in the post extensively, to read more click below on the links: Chronic cough is defined as a cough that lasts more than 8 weeks duration. For patients with underlying diseases it is called refractory chronic cough, for patients with no cause, it is called unexplained chronic cough.

Chronic Cough; Management and Diagnosis

Habit Cough

Gefapixant would be administered as a 45mg tablet dosed at twice daily. P2X3 receptors are one of the receptor types found on sensory nerve fibers, predominantly C fibers, in the airway lining.  Blocking them is thought to reduce sensory C fiber activation and subsequently, coughing.

For gefapixant, the FDA is basing its decision on some mixed data from two Phase III trials dubbed COUGH-1 and COUGH-2. Researchers linked the 45 mg dose to an 18.5% estimated relative risk reduction in 24-hour cough frequency in COUGH-1, meeting the primary endpoint (p=0.041). In COUGH-2, the same dose led to a 14.6% relative risk reduction (p=0.031). The 15 mg dose, however, failed in both trials.

If you suffer from chronic cough, it is important to try and first determine the cause of it before taking a medication such as gefapixant. Only after testing is done and meeting with your doctor, a medication such as gefapixant should be used.

There is no current branded name yet for gefapixant and the cost of the medication has not been determined yet. If the FDA does approve gefapixant, please check back for more information on it.

Filed Under: Allergy Medicine, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

May 24, 2022

Lirentelimab study for Chronic Urticaria (Hives)

lirentelimab

May 24, 2022

Dupixent for EoE (Eosinophilic Esophagitis); FDA approved and New Dosing

dupixent for eoe

April 30, 2022

What are the best foods for Asthma?

best foods for asthma

April 26, 2022

Best Nasal Polyps Treatment

best nasal polyps treatment

April 19, 2022

Fasenra for Nasal Polyps, a new treatment option

fasenra for nasal polyps

April 19, 2022

Asivatrep a new topical treatment for Eczema

asivatrep cream

April 3, 2022

Kiwi Allergy can come in many flavors

Kiwi allergy

March 15, 2022

Ana o 3 IgE in diagnosing Cashew Nut Allergy

Ana o 3

March 13, 2022

Does Expired Albuterol work?

expired albuterol

March 8, 2022

Itepekimab in Asthma and COPD

itepekimab for asthma

Read More Posts...

Follow Us…

© 2022 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page